Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
复制标题
DOI：
10.4161/hv.3.5.4175
复制
发表时间：
2007-09-01
期刊：
影响因子：
--
通讯作者：
Smith, Larry R.
中科院分区：
文献类型：
--
作者：
Jimenez, Gretchen S.;Planchon, Rodrick;Smith, Larry R.
含有保守抗原的下一代流感疫苗可增强对季节性或大流行性流感病毒株的免疫力。使用基于质粒DNA（pDNA）的疫苗方法，我们系统地测试了来自共有序列的NP、M1和M2抗原的组合，用于针对致死性流感攻击的保护，并比较了用于辅助低pDNA疫苗剂量的制剂。Vaxfectin p（TM）配制的NP + M2在最低pDNA剂量下提供最高水平的保护。用低剂量的HA pDNA证实了Vaxfectin（TM）的佐剂性。这些有希望的概念验证数据支持Vaxfectin（TM）配制的编码NP + M2共有蛋白的pDNA的临床开发。
Next generation influenza vaccines containing conserved antigens may enhance immunity against seasonal or pandemic influenza virus strains. Using a plasmid DNA (pDNA)-based vaccine approach, we systematically tested combinations of NP, M1 and M2 antigens derived from consensus sequences for protection against lethal influenza challenge and compared formulations for adjuvanting low pDNA vaccine doses. The highest level of protection at the lowest pDNA doses was provided by Vaxfectin p (TM)-formulated NP + M2. Vaxfectin (TM) adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin (TM)-formulated pDNA encoding NP + M2 consensus proteins.